The Specialty Pharmacy Review Board™ – Examining Emerging Biologics for Difficult-to-treat or Severe Asthma Web Activity


Jeffrey D. Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
MagellanRx Management

Click here for biography

Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC

Click here for biography

Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health

Click here for biography

Steven G. Avey, MS, RPh, FAMCP
Vice President, Specialty
Pharmacy Programs
MedImpact Healthcare Systems, Inc.

Click here for biography



This activity will feature a multidisciplinary faculty panel who will present best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with severe asthma. This approach will enhance the audiences' ability to recommend and implement payer-specific techniques to improve the continuity of care related to the impact of asthma management strategies on clinical outcomes, value, and economic consequences for the entire health care system. The Specialty Pharmacy Review Board™ format is similar to a mock pharmacy and therapeutics committee meeting, featuring an expert panel including a leading asthma specialist, a specialty pharmacy director, and managed care medical and pharmacy directors.

At the conclusion of this activity, participants should be able to demonstrate improved ability to: 


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number -  JA4008162-9999-19-602-H01-P)

Type of Activity: Application

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Name of Faculty or Presenter Reported Financial Relationship
Jeffrey Dunn, PharmD, MBA Dr. Dunn has nothing to disclose
Michael Wechsler, MD

Consulting Fees (ex. advisory boards) – AstraZeneca, Sanofi, Regeneron
Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Teva
Pharmaceutical Industries, Novartis Pharmaceuticals
Contracted Research – Sanofi, Regeneron Pharmaceuticals, Teva
Pharmaceutical Industries, AstraZeneca, Novartis Pharmaceuticals

Edmund Pezalla, MD, MPH

Consulting Fees (ex. advisory boards) – Regeneron‐Sanofi Alliance

Steven G. Avey, MS, RPh, FAMCP

Consulting Fees (ex. advisory boards) – Sanofi Genzyme

The PIM planners and managers have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.


There is no fee for this educational activity.